Table 1.
Baseline characteristics (N = 239)
| Value | |
|---|---|
| Age, median (range),* y | 48 (18-85) |
| Female | 138 (58) |
| KPS* | |
| 80%-100% | 131 (84) |
| <80% | 25 (16) |
| Missing, n | 83 |
| WBC,* median (range) | 4.2 (0.01-205) |
| Missing, n | 1 |
| Peripheral blood blast %,* median (range) | 0.2 (0.2-97) |
| Missing, n | 10 |
| Ph+ | 61 (25.5) |
| t(4,11) | 28 (12) |
| Any cytogenetic abnormality | 164 (69) |
| CNS disease | |
| At diagnosis | 15 (6.5) |
| At relapse/progression | 39 (17) |
| At blinatumomab initiation | 9 (4) |
| Extramedullary disease | 10 (4) |
| No. of therapies before blinatumomab, median (range) | 1 (1-7) |
| Missing, n | 1 |
| Blinatumomab as first salvage | 126 (53) |
| Blinatumomab as second salvage | 51 (21) |
| Blinatumomab as third salvage or beyond | 62 (26) |
| No. of patients with ≥3 therapies | 61 (26) |
| Primary refractory | 55 (24) |
| Time to progression after induction, y | |
| <1 | 93 (40) |
| ≥1-<2 | 45 (19) |
| ≥2-<3 | 16 (7) |
| ≥3 | 18 (7.5) |
| Allo-HCT before blinatumomab | 46 (19) |
| Previous treatment with inotuzumab ozogamicin | 22 (9) |
| Blinatumomab with TKI | 29 (12) |
| Blinatumomab with ponatinib | 16 (7) |
| Blinatumomab with dasatinib | 13 (5) |
| Blinatumomab given for MRD | 12 (5) |
| Standard blinatumomab dosing† | 218 (91) |
| MRD dosing8 | 12 (5) |
| Reduced dose due to anticipated tolerance | 9 (4) |
Values are n (%) unless otherwise noted. MRD dosing: cycle 1: 28 mcg/day continuous IV infusion on days 1-28 of a 42-day cycle. Consolidation, cycle 2-4: 28 mcg/day continuous IV infusion on days 1-28 of a 42-day cycle.
KPS, Karnofsky performance status.
*
At blinatumomab initiation.
†
Continuous infusion of 9 μg/kg for 1 week followed by 28 μg/kg infusion for 3 weeks in 6 weekly cycles.